Originally published as JCO Early Release 10.1200/JCO.2005.05.160 on April 18 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bander, N. H. Articles by Goldsmith, S. J. Search for Related Content PubMed PubMed Citation Articles by Bander, N. H. Articles by Goldsmith, S. J. Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Trial of ¹⁷⁷Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

From the Department of Urology, Division of Hematology and Medical Oncology; Department of Medicine, Division of Nuclear Medicine; Department of Radiology, Weill Medical College of Cornell University, New York, NY

Address reprint requests to Neil H. Bander, MD, Weill Medical College of Cornell University, 525 E 68th St, E-300, New York, NY 10021; e-mail: nhbander{at}med.cornell.edu

PURPOSE: To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response, pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of ¹⁷⁷Lutetium-labeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients with androgen-independent prostate cancer (PC).

PATIENTS AND METHODS: Thirty-five patients with progressing androgen-independent PC received ¹⁷⁷Lu-J591. All patients underwent ¹⁷⁷Lu-J591 imaging, PK, and biodistribution determinations. Patients were eligible for up to three retreatments.

RESULTS: Thirty-five patients received ¹⁷⁷Lu-J591, of whom 16 received up to three doses. Myelosuppression was dose limiting at 75 mCi/m², and the 70-mCi/m² dose level was determined to be the single-dose MTD. Repeat dosing at 45 to 60 mCi/m² was associated with dose-limiting myelosuppression; however, up to three doses of 30 mCi/m² could be safely administered. Nonhematologic toxicity was not dose limiting. Targeting of all known sites of bone and soft tissue metastases was seen in all 30 patients with positive bone, computed tomography, or magnetic resonance images. No patient developed a human anti-J591 antibody response to deimmunized J591 regardless of number of doses. Biologic activity was seen with four patients experiencing 50% declines in prostate-specific antigen (PSA) levels lasting from 3+ to 8 months. An additional 16 patients (46%) experienced PSA stabilization for a median of 60 days (range, 1 to 21+ months).

CONCLUSION: The MTD of ¹⁷⁷Lu-J591 is 70 mCi/m². Multiple doses of 30 mCi/m² are well tolerated. Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation.

Supported in part by National Institutes of Health General Clinical Research Center Program (NCRR grant M01RR00047); the Cancer Research Institute; the David H. Koch Foundation; the Peter Sacerdote Foundation; the Robert H. McCooey Memorial Cancer Research Fund; BZL Biologics Inc; and Millennium Pharmaceuticals Inc.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?
  Andrew M. Scott
  JCO 2005 23: 4567-4569 [Full Text]

This article has been cited by other articles:

				S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, M. G. Pomper, et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res., September 1, 2009; 69(17): 6932 - 6940. [Abstract] [Full Text] [PDF]

				B. Turkbey, P. S. Albert, K. Kurdziel, and P. L. Choyke Imaging Localized Prostate Cancer: Current Approaches and New Developments Am. J. Roentgenol., June 1, 2009; 192(6): 1471 - 1480. [Abstract] [Full Text] [PDF]

				A. L. Harzstark and E. J. Small Immunotherapeutics in Development for Prostate Cancer Oncologist, April 1, 2009; 14(4): 391 - 398. [Abstract] [Full Text] [PDF]

				A. B. Apolo, N. Pandit-Taskar, and M. J. Morris Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer J. Nucl. Med., December 1, 2008; 49(12): 2031 - 2041. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar, J. A. O'Donoghue, M. J. Morris, E. A. Wills, L. H. Schwartz, M. Gonen, H. I. Scher, S. M. Larson, and C. R. Divgi Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy J. Nucl. Med., July 1, 2008; 49(7): 1066 - 1074. [Abstract] [Full Text] [PDF]

				M. J. Morris, N. Pandit-Taskar, C. R. Divgi, S. Bender, J. A. O'Donoghue, A. Nacca, P. Smith-Jones, L. Schwartz, S. Slovin, R. Finn, et al. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2707 - 2713. [Abstract] [Full Text] [PDF]

				M. I. Milowsky, D. M. Nanus, L. Kostakoglu, C. E. Sheehan, S. Vallabhajosula, S. J. Goldsmith, J. S. Ross, and N. H. Bander Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors J. Clin. Oncol., February 10, 2007; 25(5): 540 - 547. [Abstract] [Full Text] [PDF]

				S. Aggarwal, P. Singh, O. Topaloglu, J. T. Isaacs, and S. R. Denmeade A dimeric Peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res., September 15, 2006; 66(18): 9171 - 9177. [Abstract] [Full Text] [PDF]

				C. P. Tarassoff, P. M. Arlen, and J. L. Gulley Therapeutic vaccines for prostate cancer. Oncologist, May 1, 2006; 11(5): 451 - 462. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241. [Abstract] [Full Text] [PDF]

				W. S. Webster, E. J. Small, B. I. Rini, and E. D. Kwon Prostate Cancer Immunology: Biology, Therapeutics, and Challenges J. Clin. Oncol., November 10, 2005; 23(32): 8262 - 8269. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, S. J. Goldsmith, L. Kostakoglu, M. I. Milowsky, D. M. Nanus, and N. H. Bander Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity Clin. Cancer Res., October 1, 2005; 11(19): 7195s - 7200s. [Abstract] [Full Text] [PDF]

				A. M. Scott Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter? J. Clin. Oncol., July 20, 2005; 23(21): 4567 - 4569. [Full Text] [PDF]